Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. reports groundbreaking success in its Phase 2a clinical trial for the take-home microdosing treatment MB22001, which led to a 60% reduction in depression symptoms, and 53% of patients reaching complete remission. The treatment, which was both safe and well-tolerated, marks a significant milestone in psychiatric medicine and propels the company towards late-stage drug development.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
